Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proto

Showing results (471-480 of 595) with videos related to

Pageof 60
Sort By:
Frontiers in Artificial Intelligence|February 2, 2026
Artificial intelligence and precision medicine: a pilot study predicting optimal ceftaroline dosage for pediatric patientsMaria Frasca, Gianluca Gazzaniga, Agnese Graziosi, et al.
Oncology Reports|April 10, 2003
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposesGiovanni Mantovani, Elena Massa, Giorgio Astara, et al.
International Journal of Oncology|January 15, 2002
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicityGiovanni Mantovani, Ernesto Proto, Elena Massa, et al.
ESMO Open|April 10, 2019
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsGiovanni Fucà, Giulia Galli, Marta Poggi, et al.
Cancers|April 3, 2021
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic ProgressionArsela Prelaj, Chiara Carlotta Pircher, Giacomo Massa, et al.
Glia|August 1, 2022
Novel potent liposome agonists of triggering receptor expressed on myeloid cells 2 phenocopy antibody treatment in cellsChristophe Boudesco, Annelies Nonneman, Alessandro Cinti, et al.
Diabetes, Obesity & Metabolism|September 30, 2025
ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swineSara Russo, Luca Proto, Manoel Galvao Neto, et al.
Clinical Lung Cancer|April 15, 2023
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative ResultsFilippo Lococo, Alessandra Cancellieri, Marco Chiappetta, et al.
ESMO Open|May 30, 2020
<i>LKB1</i> mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trialClaudio Vernieri, Monica Ganzinelli, Eliana Rulli, et al.
Cell Death & Disease|October 24, 2020
CSF1R signaling is a regulator of pathogenesis in progressive MSNellwyn Hagan, John L Kane, Deepak Grover, et al.
Pageof 60

Showing results (471-480 of 595) with videos related to

Sort By:
Pageof 60
Frontiers in Artificial Intelligence|February 2, 2026
Artificial intelligence and precision medicine: a pilot study predicting optimal ceftaroline dosage for pediatric patientsMaria Frasca, Gianluca Gazzaniga, Agnese Graziosi, et al.
Oncology Reports|April 10, 2003
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposesGiovanni Mantovani, Elena Massa, Giorgio Astara, et al.
International Journal of Oncology|January 15, 2002
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicityGiovanni Mantovani, Ernesto Proto, Elena Massa, et al.
ESMO Open|April 10, 2019
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsGiovanni Fucà, Giulia Galli, Marta Poggi, et al.
Cancers|April 3, 2021
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic ProgressionArsela Prelaj, Chiara Carlotta Pircher, Giacomo Massa, et al.
Glia|August 1, 2022
Novel potent liposome agonists of triggering receptor expressed on myeloid cells 2 phenocopy antibody treatment in cellsChristophe Boudesco, Annelies Nonneman, Alessandro Cinti, et al.
Diabetes, Obesity & Metabolism|September 30, 2025
ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swineSara Russo, Luca Proto, Manoel Galvao Neto, et al.
Clinical Lung Cancer|April 15, 2023
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative ResultsFilippo Lococo, Alessandra Cancellieri, Marco Chiappetta, et al.
ESMO Open|May 30, 2020
<i>LKB1</i> mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trialClaudio Vernieri, Monica Ganzinelli, Eliana Rulli, et al.
Cell Death & Disease|October 24, 2020
CSF1R signaling is a regulator of pathogenesis in progressive MSNellwyn Hagan, John L Kane, Deepak Grover, et al.
Pageof 60